Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients

Fukumitsu, Nobuyoshi; Uchiyama, Mayuki; Mori, Yutaka; Yanada, Shuuichi; Hatano, Takashi; Igarashi, Hiroshi; Kishimoto, Kouichi; Nakada, J; Yoshihiro, Akiko; Harada, Junta

doi:10.1053/meta.2002.33344

Cited by 16 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, another 17 articles with incomplete data or the same participants were excluded. Ultimately, 62 publications from 1997 to 2022 were enrolled [ 2 , 13 , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] ]. 44 articles assessed the diagnostic value of NTx for bone metastasis of human cancers [ 2 , 3 , 13 , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [38] , [39] , [40] , [41] ], 20 records evaluated the efficacy of prognostic prediction of NTx in human cancers [ 13 , 15 , 38 , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ].…”

Section: Resultsmentioning

confidence: 99%

N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis

Shen

Liang

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis

Shen

Liang

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…However, such markers, especially those of resorption, can also be increased as a consequence of bone loss due to androgen deprivation therapy and cannot be used alone to diagnose bone metastases. For example, NTX is not as sensitive as a bone scan for the diagnosis of bone metastases, but may provide an auxiliary diagnostic index for a bone scan (Fukumitsu et al 2002). There is evidence, however, that markers of bone turnover can aid the clinician in determining the response to therapy (Costa et al 2002).…”

Section: Diagnosismentioning

confidence: 99%

Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone

Clines

Guise²

2005

Endocr Relat Cancer

230

211

View full text Add to dashboard Cite

Calcium homeostasis is a tightly regulated process involving the co-ordinated efforts of the skeleton, kidney, parathyroid glands and intestine. Neoplasms can alter this homeostasis indirectly through the production of endocrine factors resulting in humoral hypercalcaemia of malignancy. Relatively common with breast and lung cancer, this paraneoplastic condition is most often due to tumour production of parathyroid hormone-related protein and ensuing increased osteoclastic bone resorption. Although control of hypercalcaemia is generally successful, the development of this complication is associated with a poor prognosis. The metastasis of tumour cells to bone represents another skeletal complication of malignancy. As explained in the 'seed and soil' hypothesis, bone represents a fertile ground for cancer cells to flourish. The molecular mechanisms of this mutually beneficial relationship between bone and cancer cells are beginning to be understood. In the case of osteolytic bone disease, tumour-produced parathyroid hormone-related protein stimulates osteoclasts that in turn secrete tumour-activating transforming growth factor-b that further stimulates local cancer cells. This 'vicious cycle' of bone metastases represents reciprocal bone/ cancer cellular signals that likely modulate osteoblastic bone metastatic lesions as well. The development of targeted therapies to either block initial cancer cell chemotaxis, invasion and adhesion or to break the 'vicious cycle' is dependent on a more complete understanding of bone metastases. Although bisphosphonates delay progression of skeletal metastases, it is clear that more effective therapies are needed. Cancer-associated bone morbidity remains a major public health problem, and to improve therapy and prevention it is important to understand the pathophysiology of the effects of cancer on bone. This review will detail scientific advances regarding this area.

show abstract

“…Not surprisingly, the available information on the diagnostic use of bone markers in metastatic bone disease is heterogeneous and often incongruent. The picture becomes more consistent when comparisons are made between a marker of bone turnover and specific imaging techniques, namely bone radioisotopes scans, or surgical outcomes in well‐defined groups of patients 8–11 …”

Section: Diagnostic Usementioning

confidence: 99%

“…The picture becomes more consistent when comparisons are made between a marker of bone turnover and specific imaging techniques, namely bone radioisotopes scans, or surgical outcomes in well-defined groups of patients. [8][9][10][11] Of the available bone formation markers (Table 1), serum total (TAP) and bone-specific alkaline phosphatase (BAP) usually exhibit the most pronounced changes in response to metastatic bone involvement. In most cases of advanced cancers metastatic to bone, serum TAP and BAP levels are elevated, pointing to either a strong osteoblastic component or, in lytic lesions, to active repair.…”

Section: Diagnostic Usementioning

confidence: 99%

The use of molecular markers of bone turnover in the management of patients with metastatic bone disease

Seibel

2007

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryBiochemical markers of bone turnover are widely used in clinical practice. These indices have been shown to be associated with the occurrence, prognosis and therapeutic response of malignant bone lesions. For example, markers of bone resorption are often elevated in patients with established bone metastases and while this may point to a role of these markers in the diagnostic workup of cancer patients, the available evidence does not permit any final conclusions as to the accuracy and validity of the presently used markers in the early diagnosis of bone metastases. Many bone turnover markers appear to respond to antiresorptive and antineoplastic therapies, and recent evidence from prospective trials suggests that the aim of bisphosphonate therapy should be to normalize rates of bone remodelling to optimize therapeutic and prognostic outcomes. However, it remains unknown whether the use of bone markers in the routine clinical setting has any defined beneficial effects on overall outcome in cancer patients. Clearly, bone turnover markers have insufficient diagnostic or prognostic value to be used in isolation; however, the combination of these markers with other diagnostic techniques may improve clinical assessment of patients with bone-seeking cancers. This article reviews the available evidence (as of August 2007) on the clinical use of bone turnover markers in the management of patients with metastatic bone disease.

show abstract

Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients

Cited by 16 publications

References 19 publications

N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis

N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis

Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone

The use of molecular markers of bone turnover in the management of patients with metastatic bone disease

Contact Info

Product

Resources

About